Citations

Showing 10 of 108119 citations.

HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)
Malik, Saad Ullah , Sipra, Qurat Ul Ain Riaz , Faridi, Warda, Gondal, Farva R. , Ho, Thanh P. , Riaz, Irbaz Bin , Husnain, Muhammad , Yadav, Siddhartha , Wang, Zhen , Kohli, Manish

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 26, 2019 | Volume: 17 | Issue: 3.5 | Pages: HSR19-108

10.6004/jnccn.2018.7233 Get It

Background: Four large RCTs (ASSURE, S-TARC, PROTECT, ATLAS) tested adjuvant VEGF-TKI therapy in high risk RCC. The results were variable for efficacy and there were concerns for increased toxicity and decline in quality of life (QoL). We performed an updated meta-analysis including results of ATLAS trial to asses a risk-benefit for adjuvant post-operative treatments in high risk RCC patients by assessing reported disease-free survival (DFS), overall survival (OS), and toxicity endpoints. Methods: Literature search was done using Medline, CENTRAL, and Embase. The DerSimonian and Laird random effects model was used to pool estimates for DFS, OS, and common side effects across the 4 trials. A subgroup analysis was performed for sunitinib alone because of its FDA approval. Heterogeneity was assessed with Cochrane Q statistic and was quantified with I2 test. Risk for bias was assessed using the Cochrane Collaboration’s tool. Results: The 4 RCTs included 4,820 patients. Adjuvant therapy with TKIs yielded no significant improvement in DFS or OS as compared to placebo (DFS HR=0.916; 95% CI, 0.832–1.009 and OS HR=1.09; 95% CI, 0.886–1.150). Separate analysis of DFS in sunitinib vs placebo did not show any benefit (2 studies, N=1,909; HR=0.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1.879–5.829), hypertension (RR=4.274; 95% CI, 3.452–5.292) and palmar/plantar dysesthesia (RR=20.53; 95% CI, 9.006–46.801) was observed. There was no statistically significant heterogeneity amongst included trials. QoL endpoints were inconsistently reported. Risk of bias was low. Conclusions: This pooled analysis provides further evidence that there is no OS or DFS benefit associated with adjuvant TKI treatment. There was a significantly increased risk of grade 3 or 4 toxicity in greater than half of the patient population leading to decline in QoL during TKI therapy. Carefully selected very high-risk patients who can tolerate these agents without dose modifications may benefit from adjuvant TKI approach.
Predictors of High Costs of Care among Otolaryngology Patients
Balakrishnan, Karthik , Moriarty, James P. , Rosedahl, Jordan K., Driscoll, Colin L. W., Rosedahl, Jordan, Driscoll, Colin L., Borah, Bijan J. , Balakrishnan, Karthik

Mayo Clinic

Otolaryngology–Head and Neck Surgery | March 26, 2019 | Volume: 161 | Issue: 2 | Pages: 271-277

10.1177/0194599819838843 | PMID 30909852 Get It

ObjectivesIdentify predictors of high‐cost otolaryngology care.Study DesignCross‐sectional.SettingTertiary academic multispecialty hospital.Subjects/MethodsAll patients undergoing ≥1 otolaryngologic procedures from 2011 to 2015. Encounter costs were standardized using previously described methods approximating Medicare reimbursement. Patients were stratified by adult/pediatric and inpatient/outpatient. “Outliers” were defined as total encounter costs ≥95th percentile. Logistic regression measured predictors of outlier status.ResultsIn total, 2433 adult inpatient encounters (95th percentile $57,611), 10,031 adult outpatient encounters ($10,772), 346 pediatric inpatient encounters ($84,639), and 3027 pediatric outpatient encounters ($8978) were included. For adult inpatient and outpatient, isolated head and neck oncologic procedures were the reference group. Among adult inpatients, laryngology and facial plastics procedures predicted higher odds of outlier status (odds ratio [OR] = 4.1 and 7.2). Involvement of multiple otolaryngology subspecialties increased the odds (OR = 4.7). Neck dissection and reconstructive procedures were the most common primary operations for adult inpatient outliers. For adult outpatients, several subspecialties had lower odds than head and neck (OR ≤0.44). Increased comorbidities predicted outliers for adult inpatient care (OR = 1.5); sex, age, race, and ethnicity did not. Cochlear implant was the most common primary operation among adult and pediatric outpatient outliers. Greater subspecialty involvement and increasing age predicted pediatric outpatient outliers (OR = 8.0 and 1.1); younger age and female sex predicted pediatric inpatient outliers (OR = 0.8 and 3.5). Airway procedures dominated pediatric inpatient outliers.ConclusionThis is the first large‐scale study of high‐cost otolaryngology care across multiple subspecialties. Specific procedures and subspecialties and increased comorbidities predicted high‐cost care. Contrary to previous studies, patient sex, race, and ethnicity did not.
An Elderly Woman with Abdominal Pain: Mirizzi Syndrome
Mohseni, Michael , Kruse, Brian, Graham, Charley, Mohseni, Michael M

Mayo Clinic

American Journal of Case Reports | March 26, 2019 | Volume: 20 | Issue: No issue available | Pages: 394-397

10.12659/ajcr.914642 | PMID 30910995 Get It

Gastrointestinal: Multi‐modality imaging of extraskeletal Ewing sarcoma of the stomach
Hopp, AC, Nguyen, Ba D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | March 26, 2019 | Volume: 34 | Issue: 8 | Pages: 1273-1273

10.1111/jgh.14638 | PMID 30912185 Get It

Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis
Maiers, Jessica L. , Malhi, Harmeet

Mayo Clinic

Seminars in Liver Disease | March 26, 2019 | Volume: 39 | Issue: 02 | Pages: 235-248

10.1055/s-0039-1681032 | PMID 30912096 Get It

AbstractEndoplasmic reticulum (ER) stress is a major contributor to liver disease and hepatic fibrosis, but the role it plays varies depending on the cause and progression of the disease. Furthermore, ER stress plays a distinct role in hepatocytes versus hepatic stellate cells (HSCs), which adds to the complexity of understanding ER stress and its downstream signaling through the unfolded protein response (UPR) in liver disease. Here, the authors focus on the current literature of ER stress in nonalcoholic and alcoholic fatty liver diseases, how ER stress impacts hepatocyte injury, and the role of ER stress in HSC activation and hepatic fibrosis. This review provides insight into the complex signaling and regulation of the UPR, parallels and distinctions between different liver diseases, and how ER stress may be targeted as an antisteatotic or antifibrotic therapy to limit the progression of liver disease.
Endocrine and Metabolic Diseases Among Colorectal Cancer Survivors in a Population-Based Cohort
Hawkins, Makenzie, Blackburn, Brenna E. , Rowe, Kerry , Snyder, John , Deshmukh, Vikrant , Newman, Michael , Fraser, Alison , Smith, Ken R. , Herget, Kimberly A. , Ganz, Patricia A. , Samadder, N. Jewel , Hashibe, Mia, Snyder, John

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 26, 2019 | Volume: 112 | Issue: 1 | Pages: 78-86

10.1093/jnci/djz040 | PMID 30918958 Get It

Abstract Background There are an estimated 1.4 million colorectal cancer (CRC) survivors in the United States. Research on endocrine and metabolic diseases over the long term in CRC survivors is limited. Obesity is a risk factor for CRC; thus it is of interest to investigate diseases that may share this risk factor, such as diabetes, for long-term health outcomes among CRC survivors. Methods A total of 7114 CRC patients were identified from the Utah Population Database and matched to a general population cohort of 25 979 individuals on birth year, sex, and birth state. Disease diagnoses (assessed over three time periods of 1–5 years, 5–10 years, and >10 years) were identified using electronic medical records and statewide ambulatory and inpatient discharge data. Cox proportional hazard models were used to estimate the risk of endocrine and metabolic disease. Results Across all three time periods, risks for endocrine and metabolic diseases were statistically significantly greater for CRC survivors compared with the general population cohort. At 1–5 years postdiagnosis, CRC survivors’ risk for diabetes mellitus with complications was statistically significantly elevated (hazard ratio [HR] = 1.36, 99% confidence interval [CI] = 1.09 to 1.70). CRC survivors also experienced a 40% increased risk of obesity at 1–5 years postcancer diagnosis (HR= 1.40, 99% CI= 1.66 to 2.18) and a 50% increased risk at 5–10 years postdiagnosis (HR = 1.50, 99% CI= 1.16 to 1.95). Conclusions Endocrine and metabolic diseases were statistically significantly higher in CRC survivors throughout the follow-up periods of 1–5 years, 5–10 years, and more than 10 years postdiagnosis. As the number of CRC survivors increases, understanding the long-term trajectory is critical for improved survivorship care.
Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis
Sineshaw, Helmneh M. , Jemal, Ahmedin , Ng, Kimmie , Osarogiagbon, Raymond U. , Yabroff, K. Robin , Ruddy, Kathryn J. , Osarogiagbon, Raymond U , Yabroff, K Robin , Freedman, Rachel A.

Mayo Clinic

JNCI Cancer Spectrum | March 25, 2019 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/jncics/pkz021 | PMID 31119208 Get It

Abstract Background Little is known about patterns of and factors associated with treatment for de novo metastatic cancer patients who die soon after diagnosis. In this study, we examine treatment patterns for patients newly diagnosed with metastatic lung, colorectal, breast, or pancreatic cancer who died within 1 month of diagnosis. Methods We identified 100 848 adult patients in the National Cancer Database with de novo metastatic lung, colorectal, breast, and pancreatic cancer, diagnosed between 2004 and 2014 and who died within 1 month. We performed descriptive and multivariable logistic regression analyses to examine receipt of surgery, chemotherapy, radiation, and hormonal therapy by cancer type, adjusting for sociodemographic and clinical variables. Results Treatment substantially varied by cancer type, over time, age, insurance, and facility type. Surgery ranged from 0.4% in pancreatic to 28.3% in colorectal cancer (CRC) patients, chemotherapy from 5.8% among CRC to 11% in lung and breast cancer patients, and radiotherapy from 1.3% in pancreatic to 18.7% in lung cancer patients. Use of some treatments (eg, surgery for CRC and breast cancer) progressively declined between 2004 and 2014. Compared with lung cancer patients treated at National Cancer Institute-designated cancer centers, those treated at community cancer centers had 48% lower odds of radiation. Conclusions Treatment of patients diagnosed with imminently fatal de novo metastatic cancer varied markedly by cancer type and patient/facility characteristics. These variations warrant more research to better identify patients with imminently fatal de novo metastatic cancer who may not benefit from aggressive and expensive therapies.
Paclitaxel-Based Therapies for Patients With Peripheral Artery Disease
Dake, Michael D. , Misra, Sanjay , Misra, Sanjay , Misra, Sanjay

Mayo Clinic

Circulation | March 25, 2019 | Volume: 139 | Issue: 13 | Pages: 1565-1567

10.1161/circulationaha.118.039510 | PMID 30908101 Get It

Impact of Chronic Kidney Disease on Outcomes in Cirrhosis
Wong, Florence , Reddy, K. Rajender , O’Leary, Jacqueline G. , Biggins, Scott W. , García‐Tsao, Guadalupe , Maliakkal, Benedict, Lai, Jennifer C. , Fallon, Michael B. , Vargas, Hugo E. , Subramanian, Ram, Thuluvath, Paul J. , Kamath, Patrick S. , Bajaj, Jasmohan S. , Lai, Jennifer , Bajaj, Jasmohan S , Wong, Florence , Vargas, Hugo E , Tandon, Puneeta , García–Tsao, Guadalupe , Thacker, Leroy R.

Mayo Clinic

Liver Transplantation | March 25, 2019 | Volume: 25 | Issue: 6 | Pages: 870-880

10.1002/lt.25454 | PMID 30908855 Get It

We hypothesize that the prevalence of chronic kidney disease (CKD) among patients with cirrhosis has increased due to the increased prevalence of CKD‐associated comorbidities, such as diabetes. We aimed to assess the characteristics of hospitalized patients with cirrhosis with CKD and its impact on renal and patient outcomes. The North American Consortium for the Study of End‐Stage Liver Disease (NACSELD) prospectively enrolled nonelectively admitted patients with cirrhosis and collected data on demographics, laboratory results, in‐hospital clinical course, and postdischarge 3‐month outcomes. CKD positive (CKD+) patients, defined as having an estimated glomerular filtration rate (eGFR; Modification of Diet in Renal Disease–4 variable formula) of ≤60 mL/minute for >3 months, were compared with chronic kidney disease negative (CKD–) patients for development of organ failures, hospital course, and survival. There were 1099 CKD+ patients (46.8% of 2346 enrolled patients) who had significantly higher serum creatinine (2.21 ± 1.33 versus 0.83 ± 0.21 mg/dL in the CKD– group) on admission, higher prevalence of nonalcoholic steatohepatitis cirrhosis etiology, diabetes, refractory ascites, and hospital admissions in the previous 6 months compared with the CKD– group (all P < 0.001). Propensity matching (n = 922 in each group) by Child‐Pugh scores (9.78 ± 2.05 versus 9.74 ± 2.04, P = 0.70) showed that CKD+ patients had significantly higher rates of superimposed acute kidney injury (AKI; 68% versus 21%; P < 0.001) and eventual need for dialysis (11% versus 2%; P < 0.001) than CKD– patients. CKD+ patients also had more cases of acute‐on‐chronic liver failure as defined by the NACSELD group, which was associated with reduced 30‐ and 90‐day overall survival ( P < 0.001 for both). A 10 mL/minute drop in eGFR was associated with a 13.1% increase in the risk of 30‐day mortality. In conclusion, patients with CKD should be treated as a high‐risk group among hospitalized patients with cirrhosis due to their poor survival, and they should be monitored carefully for the development of superimposed AKI.
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Barrionuevo, Patricia , Kapoor, Ekta , Asi, Noor, Alahdab, Fares , Mohammed, Khaled , Benkhadra, Khalid, Almasri, Jehad , Farah, Wigdan , Muthusamy, Kalpana , Nofal, Alaa Al , Haydour, Qusay, Murad, M. Hassan , Sarigianni, Maria, Murad, Mohammad Hassan, Murad, M Hassan , Al Nofal, Alaa , Sarigianni, Maria , Wang, Zhen , Farah, Wigdan , Alahdab, Fares

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 25, 2019 | Volume: 104 | Issue: 5 | Pages: 1623-1630

10.1210/jc.2019-00192 | PMID 30907957 Get It

Abstract Background Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women. We aimed to determine the comparative effectiveness of various available pharmacological therapies. Methods We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ISI Web of Science, and Scopus for randomized controlled trials that enrolled postmenopausal women with primary osteoporosis and evaluated the risk of hip, vertebral, or nonvertebral fractures. A network meta-analysis was conducted using the multivariate random effects method. Results We included 107 trials (193,987 postmenopausal women; mean age, 66 years; 55% white; median follow-up, 28 months). A significant reduction in hip fractures was observed with romosozumab, alendronate, zoledronate, risedronate, denosumab, estrogen with progesterone, and calcium in combination with vitamin D. A significant reduction in nonvertebral fractures was observed with abaloparatide, romosozumab, denosumab, teriparatide, alendronate, risedronate, zoledronate, lasofoxifene, tibolone, estrogen with progesterone, and vitamin D. A significant reduction in vertebral fractures was observed with abaloparatide, teriparatide, parathyroid hormone 1-84, romosozumab, strontium ranelate, denosumab, zoledronate, risedronate, alendronate, ibandronate, raloxifene, bazedoxifene, lasofoxifene, estrogen with progesterone, tibolone, and calcitonin. Teriparatide, abaloparatide, denosumab, and romosozumab were associated with the highest relative risk reductions, whereas ibandronate and selective estrogen receptor modulators had lower efficacy. The evidence for the treatment of fractures with vitamin D and calcium remains limited despite numerous large trials. Conclusions This network meta-analysis provides comparative effective estimates for the various available treatments to reduce the risk of fragility fractures in postmenopausal women.